Key Stats for IDEXX Laboratories Stock
- Past-Week Performance: -0.9%
- 52-Week Range: $356.1 to $770
- Current Price: $610.5
What Happened?
Veterinary diagnostics leader IDEXX Laboratories posted Q4 revenue of $1.09 billion, up 14%, beating estimates by $18 million while its inVue Dx analyzer drove a 51.8% surge in capital instrument revenue for full year 2025.
On February 2, CFO Andrew Emerson told analysts that inVue Dx, an in-clinic cell analysis platform that automates slide preparation and delivers AI-powered results in minutes, surpassed 6,400 placements in 2025, contributing over $75 million in revenue and approximately 200 basis points of total company growth.
Full year organic revenue grew 10% to $4.3 billion, outpacing IDEXX’s own initial guidance range of 6% to 9% by roughly 200 basis points, while peer Zoetis (ZTS) flagged declining therapeutic visits and dose volumes among younger, budget-constrained pet owners
Furthermore, Emerson stated on the Q4 earnings call that “we placed more than 1,900 inVue Dx instruments in the fourth quarter, contributing to a quarterly record for instrument placements and a 12% year-over-year expansion of IDEXX’s global premium instrument installed base,” anchoring 2026 guidance for 5,500 additional inVue placements.
With Cancer Dx expanding to mast cell tumor detection at mid-2026, an international lymphoma rollout confirmed for Q1 2026, and a long-term TAM of $45 billion in veterinary medical services, IDEXX’s innovation pipeline, $1.2 billion share repurchase program, and 15%-plus EPS growth algorithm position it to compound well beyond its current $603 stock price.
Wall Street’s Take on IDXX Stock
The inVue Dx placement cycle matters beyond instrument revenue because each of the 6,400 analyzers placed in 2025 now anchors a recurring consumables stream worth $3,500 to $5,500 per unit annually.
IDEXX grew full year revenue 10.4% to $4.3 billion in 2025, and the TIKR model projects that cadence sustaining at an 8.8% revenue CAGR through 2030, reaching $6.6 billion while EBIT margins expand from 31.6% to 35.6%.
EPS hit $13.08 in 2025, up 22.6% year over year, and the TIKR mid-case model targets $23.28 by 2030, representing an 11.7% EPS CAGR driven by operating leverage and continued share repurchases reducing the diluted share count 1% to 2% annually.
Meanwhile, nine of 13 analysts covering IDXX carry a buy or outperform rating, with a mean price target of $750.23 and a median of $775.00, implying roughly 23% upside from the current $610.45 price as the Street prices in the Cancer Dx and inVue consumables ramp.
The spread between the Street’s low target of $470 and high of $823 reflects a genuine fork: the bear case prices in a prolonged -2% U.S. clinic visit decline, while the $823 high captures a scenario where the aging pandemic pet cohort accelerates non-wellness visit recovery.
What Does the Valuation Model Say?
TIKR’s mid-case fair value of $998.68 implies 63.6% total return over 4.8 years at a 10.8% IRR, anchored by an 8.8% revenue CAGR and net income margins expanding from 24.6% in 2026 to 25.9% by 2030.
The market is pricing IDXX as a slowing diagnostics business, but a 12% global premium instrument installed base expansion in 2025 and a $1.1 billion long-term Cancer Dx TAM argue otherwise.
IDEXX’s Cancer Dx panel already reached 6,000 reference lab customers in its first year, with 18% of those new to IDEXX entirely, proving the innovation is expanding the addressable customer base, not just monetizing the existing one.
CEO Jay Mazelsky confirmed that diagnostic frequency, the share of clinic visits that include blood work, expanded by 100 basis points in 2025, double the historical rate, signaling structural utilization gains that persist regardless of visit volume headwinds.
Accordingly, a sustained -2% or steeper U.S. clinic visit decline beyond 2026 would pressure CAG Diagnostics recurring revenue below the 8% to 10% organic growth guide and compress the margin expansion path the TIKR model depends on.
Watch Q1 2026 CAG Diagnostics recurring revenue, guided at 8.5% to 10.5% organic, as the first hard confirmation that inVue consumables pull-through and Cancer Dx adoption are inflecting as modeled.
Should You Invest in IDEXX Laboratories, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up IDXX stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track IDEXX Laboratories, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze IDEXX stock on TIKR for Free →
